| Outcome Measures: |
Primary: Change in liver fat content, Quantified by MRI-PDFF, Baseline to 24 weeks | Secondary: Change in pancreatic fat content, Measured by DEXA, Baseline to 24 weeks|Change in body weight, Measured by DEXA, Baseline to 24 weeks|Change in body mass index, Measured by DEXA, Baseline to 24 weeks|Change in total fat percentage, Measured by DEXA, Baseline to 24 weeks|Change in lean muscle mass, Measured by DEXA, Baseline to 24 weeks|Change in bone mineral content, Measured by DEXA, Baseline to 24 weeks|Change in controlled attenuation parameter, Measured by transient elastography, Baseline to 24 weeks|Change in liver stiffness measurement, Measured by transient elastography, Baseline to 24 weeks|Change in aspartate aminotransferase, Baseline to 24 weeks|Change in alanine aminotransferase, Baseline to 24 weeks|Change in gamma-glutamyl transpeptidase, Baseline to 24 weeks|Change in serum creatinine concentrations, Baseline to 24 weeks|Change in HbA1c, Baseline to 24 weeks|Change in triglycerides, Baseline to 24 weeks|Change in HDL cholesterol, Baseline to 24 weeks|Change in LDL-cholesterol, Baseline to 24 weeks
|
